Cancer drug improved cognition, motor skills in small Parkinson's clinical trial
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson's disease and Lewy body dementia in a small phase I clinical trial, report researchers. In addition, the drug, nilotinib (Tasigna by Novartis), led to statistically significant and encouraging changes in toxic proteins linked to disease progression (biomarkers).
Source: ScienceDaily Headlines - Category: Science Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Dementia | Leukemia | Nilotinib | Parkinson's Disease | Science | Statistics | Tasigna | Toxicology